Other targets explored aiming to prevent macrophage activation and promote M2-like polarization include inositol-requiring enzyme 1α (IRE1α) (189), farnesoid X receptor (FXR) (190), apoptosis signal-regulating kinase 1 (ASK-1) (191) and obeticholic acid which is a strong FXR agonist with promising results from an early phase clinical trial in NASH (192). The gene discussed is MAP3K5; the disease is metabolic dysfunction-associated steatohepatitis.